display ongoing
results: demonstrated suggested inconclusive safety concern ongoing study
breast cancer - HR positive
la/mBC - HR-positive - 1st line (L1)
cyclin inhibitor
abemaciclib based treatment
abemaciclib plus aromatase inhibitor MONARCH 3
abemaciclib plus endocrine therapy MonarchE
palbociclib based treatment
palbociclib plus endocrine therapy PENELOPE-B
palbociclib plus letrozole PALOMA-1 PALOMA-2
ribociclib based treatment
ribociclib plus letrozole MONALEESA-2

Study type: